Emergent BioSolutions, Inc. (EBS)
| Market Cap | 3.05B |
| Revenue (ttm) | 1.71B |
| Net Income (ttm) | 299.20M |
| Shares Out | 53.60M |
| EPS (ttm) | 5.50 |
| PE Ratio | 10.24 |
| Forward PE | 11.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 414,156 |
| Open | 56.23 |
| Previous Close | 57.14 |
| Day's Range | 55.85 - 57.14 |
| 52-Week Range | 55.07 - 127.20 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 85.71 (+52.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a...
Financial Performance
In 2020, EBS's revenue was $1.56 billion, an increase of 40.63% compared to the previous year's $1.11 billion. Earnings were $305.10 million, an increase of 459.82%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is 85.71, which is an increase of 52.08% from the latest price.
News
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19 vaccine candidate. Emergent will p...
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its...
GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract d...
Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment
Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived the...
Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clin...
GAITHERSBURG, Md., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Im...
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investo...
New Strong Sell Stocks for August 2nd
ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations.
U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing
Drug manufacturer Emergent BioSolutions Inc on Friday said it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.
Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021.
Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant
Emergent BioSolutions Inc (NYSE: EBS) will resume production of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions...
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent's Bayview manufacturing f...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
GAITHERSBURG, Md., July 26, 2021 (GLOBE NEWSWIRE) -- An alliance of national nonprofit organizations comprised of Community Anti-Drug Coalitions of America (CADCA), Mothers Against Prescription Drug Ab...
These Companies Have Seen Large Returns From 2020 Government Investment
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial result...
Can Emergent BioSolutions Recover From Its Recent Blunders?
Yes, but it probably won't be an easy path.
Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
New York, New York--(Newsfile Corp. - June 23, 2021) - Faruqi & Faruqi, LLP, a leading minority and Woman-owned national securities law firm, is investigating potential misconduct at Emergent BioSolutio...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsui...
New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Emer...
Final Deadline Today: Rosen, Global Investor Counsel, Reminds Emergent BioSolutions Inc. Investors with Losses Over $...
New York, New York--(Newsfile Corp. - June 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between Apri...
FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions I...
Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Emergent BioSolutions ...
Final Deadline Monday: Rosen, A Top Ranked Law Firm, Reminds Emergent BioSolutions Inc. Investors with Losses Over $1...
New York, New York--(Newsfile Corp. - June 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between Apri...
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc....
LOS ANGELES--(BUSINESS WIRE)---- $EBS #EBS--DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc.